Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
First Claim
Patent Images
1. A hormonal regimen wherein at least one of the daily dosages has at least 0.5 mg of norgestrel and an estrogen component with less than 50 mcg EE equivalent.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of increasing TGF-β expression in the ovarian epithelium. HRT and OCP regimens comprising such compositions and methods are disclosed.
157 Citations
33 Claims
- 1. A hormonal regimen wherein at least one of the daily dosages has at least 0.5 mg of norgestrel and an estrogen component with less than 50 mcg EE equivalent.
- 12. A hormonal regimen wherein at least one of the daily dosages has at least 1.0 mg of ethinodiol diacetate and an estrogen component with less than 50 mcg EE equivalent.
- 23. A hormonal regimen wherein at least one of the daily dosages has greater than 10 mg of at least one progestin selected from the group consisting of norethindrone, norethinodryl and norethinodrel and an estrogen component with less than 50 mcg EE equivalent.
Specification